Novel Agents for Treatment of High-risk COVID-19 Positive Patients

NCT04374019 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

13

Enrollment

OTHER

Sponsor class

Stopped slow accrual,

Conditions

COVID
Sars-CoV2

Interventions

DRUG: Ivermectin
DRUG: Camostat Mesilate
DIETARY_SUPPLEMENT: Artemesia annua
DRUG: Artesunate

Sponsor

Susanne Arnold